Asparlas 3,750 unit/5 ML vial 5ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQWH3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $81,462
Award facts
- Contract value 100% obligated
- $81,462.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $81,462.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of 3,750 units of Asparlas (5 ML vials). The contract is firm fixed-price with no set-aside designation and carries an ultimate completion date of January 15, 2026. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceutical products to Department of Defense military healthcare facilities worldwide. The parent IDC, designated SPE2DR, was awarded on November 13, 2025, with a ceiling value of $499,999,999 and extends through December 31, 2036.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity through the Defense Logistics Agency's Medical Supply Chain division, supplying an extensive portfolio of branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support DoD healthcare operations. Asparlas (asparaginase Erwinia chrysanthemi) is a specialty pharmaceutical used in acute lymphoblastic leukemia treatment, reflecting the company's capability to deliver critical oncology and specialty pharmaceutical products. With no identified subcontractor relationships and consistent performance across multiple therapeutic categories, DMS Pharmaceutical Group operates as a direct supplier under the PPV-G GEN V framework to ensure reliable pharmaceutical supply chain support for military medical facilities.
Quick answers
Who was awarded contract SPE2DR26FQWH3?
SPE2DR26FQWH3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 23, 2025.
How much is contract SPE2DR26FQWH3 worth?
The government has obligated $81,462 on SPE2DR26FQWH3.
Is contract SPE2DR26FQWH3 an order under another contract?
Yes. SPE2DR26FQWH3 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWH3 competed?
The extent of competition for SPE2DR26FQWH3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award